Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q2 EPS by 9c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $80.50 +2.04%
Revenue Growth %: +89.8%
Financial Fact:
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES: -19.42M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Revenue Growth %: +89.8%
Financial Fact:
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES: -19.42M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($0.20), $0.09 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $23.53 million versus the consensus estimate of $21.74 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- SanDisk (SNDK) PT Raised to $3,000 at Bernstein SocGen Group, 'We believe this is not understood by the Street'
- Freedom Broker Starts American States Water (AWR) at Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
